Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HNF4A | P41235 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27561165 | 0.83 | TRPA1 (0.38) | IDH1ALOX5KEAP1MEN1HPGD | |
| SCHEMBL16720697 | 0.82 | KDM4E (0.43) | KEAP1HPGDALOX15HSD17B10 | |
| SCHEMBL8802600 | 0.78 | BCL2 (0.44) | BCL2BCL2L1IDH1CALM1ALOX5 | |
| SCHEMBL8466360 | 0.78 | CALM1 (0.55) | BCL2BCL2L1IDH1CALM1CYP3A4 | |
| SCHEMBL7465411 | 0.78 | CALM1 (0.44) | BCL2BCL2L1CALM1MEN1CYP3A4 | |
| SCHEMBL721135 | 0.78 | CALM1 (0.44) | BCL2BCL2L1CALM1ALOX5KEAP1 | |
| SCHEMBL27703315 | 0.77 | KDM4E (0.43) | MEN1HPGDALOX15KMT2AHSD17B10 | |
| SCHEMBL7459473 | 0.76 | CALM1 (0.42) | BCL2BCL2L1CALM1ALOX5MEN1 | |
| SCHEMBL28815316 | 0.76 | CALM1 (0.42) | CALM1CYP3A4ALOX15 | |
| SCHEMBL7453243 | 0.76 | CALM1 (0.42) | BCL2BCL2L1IDH1CALM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46830-E1 | Method for solid phase peptide synthesis | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2018-05-08 | — | — | US | disclosed |
| US-20170283478-A1 | PROCESS FOR PREPARATION OF LIRAGLUTIDE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-10-05 | — | — | US | disclosed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2016005960-A1 | PROCESS FOR PREPARATION OF LIRAGLUTIDE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2016-01-14 | — | — | WO | disclosed |
| US-9040480-B2 | Synthesis of glucagon-like peptide | LONZA AG (CH) | 2015-05-26 | — | — | US | disclosed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20130324699-A1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE | LONZA AG (CH) | 2013-12-05 | — | — | US | disclosed |
| US-8445433-B2 | Synthesis of glucagon-like peptide | LONZA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-7939629-B2 | Method for solid phase peptide synthesis | LONZA AG (CH) | 2011-05-10 | — | — | US | disclosed |
| EP-1987052-B1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDES | LONZA AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| WO-2006032457-A9 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006045503-A1 | METHOD FOR SOLID PHASE PEPTIDE SYNTHESIS | LONZA AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006032457-A1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| EP-0848694-A4 | REDUCING ESTROGENICITY OF ALKOXYLATED COMPOUNDS AND PRODUCTS THEREOF | WITCO CORP (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0848694-A1 | REDUCING ESTROGENICITY OF ALKOXYLATED COMPOUNDS AND PRODUCTS THEREOF | WITCO CORPORATION (US) | 1998-06-24 | — | — | EP | disclosed |
| EP-0804191-A1 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR | Sugen, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997006125-A1 | REDUCING ESTROGENICITY OF ALKOXYLATED COMPOUNDS AND PRODUCTS THEREOF | WITCO CORPORATION (US) | 1997-02-20 | — | — | WO | disclosed |
| WO-1995019169-A2 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR | SUGEN, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| US-4605759-A | ACIDIFYING THE REACTION PRODUCT OF GLYCINE, A BENZALDEHYDE AND GROUP 1 METAL HYDROXIDE USING WATER/SOLVENT MIXTURE AND A PHASE TRANSFER AGENT | MITSUI TOATSU CHEMICALS, INC. (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0051023-A1 | Derivatives of the benzoyl and alpha hydroxybenzyl-phenyl osides family, method for their preparation and their therapeutic application | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324699-A1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GIPR | BCL2 4033/4885BCL2L1 2222/4885IDH1 2790/4885 |
| US-20170283478-A1 | PROCESS FOR PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, GCG | BCL2 2759/4885BCL2L1 2977/4885IDH1 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.